Opthea (OPT) announced updates on its Phase 3 clinical program, including the termination of COAST and accelerated topline results from its ...

The announcement follows the decision to discontinue the COAST and ShORe trials in wet age-related macular degeneration after the COAST trial failed to meet its primary endpoint.

Opthea determined that the most appropriate course of action for wet AMD patients, shareholders, and other stakeholders was to accelerate the ShORe trial topline data readout, including in ...

An add-on agent designed to boost drugs that treat age-related macular degeneration failed to show any benefit in two phase 3 ...

“At this stage, no decision has yet been taken with respect to either trial, including whether to discontinue activities for the COAST trial or accelerate and unmask the ShORe trial,” Opthea ...

Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to discard the entire ...

Australian biotech Opthea (Nasdaq: OPT) is cutting around two-thirds of its workforce, as the company moves to curb spending ...

Opthea determined that the most appropriate course of action for wet AMD patients, shareholders, and other stakeholders was to accelerate the ShORe trial topline data readout, including in ...

Hopes that ShORe could rescue the programme seem slim ... with the DFA Investors […] to explore possible options for Opthea in respect of its clinical trial programme and with a view to ...

ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea and DFA Investors agreed to terminate both COAST and ShORe ...

Opthea Limited (OPT), a biopharmaceutical firm, has decided to discontinue its Phase 3 clinical program for sozinibercept in treating wet age-related macular degeneration (wet AMD). This decision ...

ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52Opthea and DFA ...